Hikma expands injection business with acquisition of Xellia assets

Hikma pharmaceutical company announced on Monday that it had agreed to buy the parts Xellia pharmaceutical companya Copenhagen-based specialist company focused on providing anti-infective and other critical care therapies for up to $185 million.

Hikma will acquire a portion of Xellia’s U.S. ready-to-dose (FDF) business and assets, including its commercial portfolio and diversified product pipeline, manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and research and development center in Zagreb, Croatia.

The acquisition will add eight approved and commercialized injectable products to Hikma’s U.S. portfolio and 11 ready-to-drink products.

Xellia’s commercial portfolio includes ready-to-use Vanco Ready® (vancomycin), launched in 2019, and other anti-infectives. These products are currently manufactured by a third party, and Hikma will maintain these manufacturing agreements until it upgrades its Cleveland facility to move production of these products in-house.

Chief Executive Officer Riad Mishlawi said: “Hikma has grown into one of the top three suppliers of sterile injectable pharmaceuticals in the U.S. thanks to our extensive history of successful value-enhancing acquisitions such as this one.

“This acquisition will significantly increase the scale of our U.S. operations and expand our U.S. manufacturing capabilities and injection portfolio by adding complex technologies. I am confident that this transaction will provide significant future value to our injectables business, supporting growth over the medium term.”